Nucleic acid aptamers for target validation and therapeutic applications.
暂无分享,去创建一个
J. M. Healy | D. Grate | M. Stanton | Judith M Healy | Martin Stanton | P Shannon Pendergrast | P. S. Pendergrast | H. Marsh | H Nicholas Marsh | Dilara Grate | P. Pendergrast
[1] C. Bennett,et al. Efficiency of antisense oligonucleotide drug discovery. , 2002, Antisense & nucleic acid drug development.
[2] P. D. Cook,et al. Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. , 1995, Nucleic acids research.
[3] O. Heidenreich,et al. Structure-function relationship of hammerhead ribozymes as probed by 2'-modifications. , 1991, Nucleic acids symposium series.
[4] T. Tuschl,et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.
[5] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[6] S. Stavchansky,et al. Quantitative determination of short single-stranded oligonucleotides from blood plasma using capillary electrophoresis with laser-induced fluorescence. , 1997, Analytical chemistry.
[7] P. Mann,et al. An Evaluation of the Toxicities of 2' -Fluorouridine and 2'-Fluorocytidine-HCI in F344 Rats and Woodchucks (Marmota monax) , 1999, Toxicologic pathology.
[8] R. Iggo,et al. Induction of an interferon response by RNAi vectors in mammalian cells , 2003, Nature Genetics.
[9] N. Janjić,et al. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. , 1999, The American journal of pathology.
[10] C. Heldin,et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. , 2001, Cancer research.
[11] M. Yaffe,et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. , 1999, Science.
[12] L. Hyman,et al. Epidemiology of eye disease in the elderly , 1987, Eye.
[13] S. Gill,et al. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. , 1999, Journal of chromatography. B, Biomedical sciences and applications.
[14] E. Vermaas,et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin , 1992, Nature.
[15] Sverdrup,et al. Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination. , 1999, Drug discovery today.
[16] George Georgiou,et al. Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer. , 2002, Nucleic acids research.
[17] Joyce Nelson,et al. Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys , 2000, Pharmaceutical Research.
[18] M. Famulok,et al. Cytoplasmic RNA modulators of an inside-out signal-transduction cascade. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[19] Brygida Berse,et al. Vascular permeability factor (VPF, VEGF) in tumor biology , 1993, Cancer and Metastasis Reviews.
[20] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[21] Lieve Moons,et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.
[22] Michael R. Green,et al. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). , 2004, RNA.
[23] J. Lis,et al. The concentration of B52, an essential splicing factor and regulator of splice site choice in vitro, is critical for Drosophila development , 1994, Molecular and cellular biology.
[24] T. Böhm,et al. Controlling small guanine–nucleotide-exchange factor function through cytoplasmic RNA intramers , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Lis,et al. RNA aptamers as effective protein antagonists in a multicellular organism. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] L. C. Bock,et al. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. , 1993, Blood.
[27] Joan W. Miller,et al. VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.
[28] C. Vargeese,et al. Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. , 1995, Biochemistry.
[29] D. Goeddel,et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.
[30] A D Ellington,et al. RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo , 1996, Journal of virology.
[31] Tobias Sjöblom,et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. , 2002, Cancer research.
[32] [14] In vitro selection of RNA aptamers , 2000 .
[33] N. Janjić,et al. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. , 2001, Journal of the American Society of Nephrology : JASN.
[34] P. Carmeliet,et al. Role of tissue factor in embryonic blood vessel development , 1996, Nature.
[35] A. Barberis,et al. Target validation through protein-domain knockout – applications of intracellularly stable single-chain antibodies , 2002 .
[36] W. Foulds,et al. Common causes of blindness and visual handicap in the west of Scotland. , 1983, The British journal of ophthalmology.
[37] E. Pich,et al. Transgenic mice in drug dependence research. , 1998, Annals of medicine.
[38] S. Bunting,et al. Vascular endothelial growth factor, a specific regulator of angiogenesis , 1996, Current opinion in nephrology and hypertension.
[39] A. DeAnda,et al. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.
[40] J. Lis,et al. The SR protein B52/SRp55 is essential for Drosophila development , 1994, Molecular and cellular biology.
[41] Letha J. Sooter,et al. Automated acquisition of aptamer sequences. , 2002, Combinatorial chemistry & high throughput screening.
[42] E. Gilboa,et al. Inhibition of HIV-1 in CEM cells by a potent TAR decoy. , 1995, Gene therapy.
[43] S. Stavchansky,et al. Pharmacokinetics and Biodistribution of a Nucleotide-Based Thrombin Inhibitor in Rats , 1998, Pharmaceutical Research.
[44] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.